American Society of Nephrology
Founded in 1966, the American Society of Nephrology (ASN) is the world’s largest professional society devoted to the study of kidney disease. Composed of 11,000 physicians and scientists, ASN promotes expert patient care, advances medical research, and educates the renal community. ASN also informs policymakers about issues of importance to kidney doctors and their patients.
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of American Society of Nephrology
Names of Lobbyists
Firm Hired Amount American Society of Nephrology $42,500
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Fed Budget & Appropriations,
- Medicare & Medicaid,
- Medical Research & Clin Labs
Most Frequently Disclosed Bills
Bill No. Title H.R.1454 Congressional Pay Accountability Act of 2011 H.R.2969 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
RegulationsMentioned in 20 dockets; Submitted to 4 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "American Society of Nephrology" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for American Society of Nephrology
- Toggle 2 FDA Approaches to Reducing Sodium Consumption 2011
- Toggle 1 FDA Food Labeling: Revision of the Nutrition and Supplement Facts Labels 2012
- Toggle 1 HHS Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators 2011
- Toggle 1 FSIS Reducing Sodium in the Food Supply; Establishing Sodium Reduction Targets; Establishment of Dockets; Request for Comments, Data and Information 2011
Mentions in Document Text
View all mentions data for American Society of Nephrology
- Toggle 6 FDA Approaches to Reducing Sodium Consumption 2011
- Toggle 5 FDA Food Labeling: Revision of the Nutrition and Supplement Facts Labels 2012
- Toggle 4 CMS Medicare Program; Changes to the End-Stage Renal Disease Prospective Payment System for CY 2012, End-Stage Renal Disease Quality Incentive Program for PY 2013 and PY 2014; Ambulance Fee Schedule; and Durable Medical Equipment 2011
- Toggle 4 CMS Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule, DME Face-to-Face Encounters, Elimination of the Requirement for Termination of Non-Random Prepayment Complex Medical Review and Other Revisions to Part B for CY 2013 (CMS-1590-P) 2012
- Toggle 4 FSIS Reducing Sodium in the Food Supply; Establishing Sodium Reduction Targets; Establishment of Dockets; Request for Comments, Data and Information 2011
- Toggle 3 CMS Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Bad Debt Reductions for all Medicare Providers 2012
- Toggle 2 CMS Medicare, Medicaid, Children's Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests (CMS-5060-P) 2011
- Toggle 2 CMS Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2012 2011
- Toggle 1 CMS Medicare: Changes to the End-Stage Renal Disease Prospective Payment System Transition Budget-Neutrality Adjustment 2011
- Toggle 1 FDA Allocate Full Doses of Agalsidase Beta (Fabrazyme®) to U.S. Citizens Under its Consent Decree with Genzyme Corporation 2011